Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that abstracts for the luspatercept and sotatercept phase 2 clinical trials were both selected for oral presentations in the Best of Clinical Trials sessions at the 13th International Symposium on Myelodysplastic Syndromes (MDS) being held April 29th - May 2nd in Washington, D.C. Acceleron and Celgene Corporation are jointly developing luspatercept and sotatercept.
Luspatercept Oral Presentation | |||
Title: | Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study | ||
| Presenter: | Uwe Platzbecker, M.D., University Hospital in Dresden, Germany | ||
| Session: | Best of Clinical Trials II | ||
| Date/Time: | Saturday, May 2, 10:30 - 10:40 AM (EDT) | ||
| Location: | Washington Marriott Wardman Park, Hall A | ||
Sotatercept Oral Presentation | |||
| Title: | A Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion | ||
| Presenter: | Rami Komrokji, M.D., Moffitt Cancer Center | ||
| Session: | Best of Clinical Trials I | ||
| Date/Time: | Wednesday, April 29, 6:00 - 6:10 PM (EDT) | ||
| Location: | Washington Marriott Wardman Park, Hall A | ||
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases. For more information, please visit www.acceleronpharma.com.
Contacts:
Steven Ertel, 617-649-9234
Executive
Vice President and Chief Operating Officer
or
Media:
Suda
Communications LLC
Maureen L. Suda, 585-387-9248
